These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
364 related articles for article (PubMed ID: 22311987)
1. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. Doi K; Li R; Sung SS; Wu H; Liu Y; Manieri W; Krishnegowda G; Awwad A; Dewey A; Liu X; Amin S; Cheng C; Qin Y; Schonbrunn E; Daughdrill G; Loughran TP; Sebti S; Wang HG J Biol Chem; 2012 Mar; 287(13):10224-10235. PubMed ID: 22311987 [TBL] [Abstract][Full Text] [Related]
2. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. Pandey MK; Gowda K; Doi K; Sharma AK; Wang HG; Amin S PLoS One; 2013; 8(11):e78570. PubMed ID: 24223823 [TBL] [Abstract][Full Text] [Related]
3. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Chen S; Dai Y; Harada H; Dent P; Grant S Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790 [TBL] [Abstract][Full Text] [Related]
4. The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737. Boiani M; Daniel C; Liu X; Hogarty MD; Marnett LJ J Biol Chem; 2013 Mar; 288(10):6980-90. PubMed ID: 23341456 [TBL] [Abstract][Full Text] [Related]
5. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Rahmani M; Aust MM; Hawkins E; Parker RE; Ross M; Kmieciak M; Reshko LB; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Grant S Haematologica; 2015 Dec; 100(12):1553-63. PubMed ID: 26452980 [TBL] [Abstract][Full Text] [Related]
6. Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression. Doi K; Liu Q; Gowda K; Barth BM; Claxton D; Amin S; Loughran TP; Wang HG Cancer Biol Ther; 2014 Aug; 15(8):1077-86. PubMed ID: 24842334 [TBL] [Abstract][Full Text] [Related]
7. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Rooswinkel RW; van de Kooij B; Verheij M; Borst J Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003 [TBL] [Abstract][Full Text] [Related]
8. Purported Mcl-1 inhibitor marinopyrrole A fails to show selective cytotoxicity for Mcl-1-dependent cell lines. Eichhorn JM; Alford SE; Hughes CC; Fenical W; Chambers TC Cell Death Dis; 2013 Oct; 4(10):e880. PubMed ID: 24157874 [No Abstract] [Full Text] [Related]
9. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609 [TBL] [Abstract][Full Text] [Related]
12. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795 [TBL] [Abstract][Full Text] [Related]
13. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. Mazumder S; Choudhary GS; Al-Harbi S; Almasan A Cancer Res; 2012 Jun; 72(12):3069-79. PubMed ID: 22525702 [TBL] [Abstract][Full Text] [Related]
14. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells. Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900 [TBL] [Abstract][Full Text] [Related]
15. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis. Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663 [TBL] [Abstract][Full Text] [Related]
16. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Chen S; Dai Y; Pei XY; Grant S Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519 [TBL] [Abstract][Full Text] [Related]
17. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Jane EP; Premkumar DR; DiDomenico JD; Hu B; Cheng SY; Pollack IF Mol Cancer Ther; 2013 Mar; 12(3):326-38. PubMed ID: 23325792 [TBL] [Abstract][Full Text] [Related]
18. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351 [TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017 [TBL] [Abstract][Full Text] [Related]
20. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1. Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]